Cannabis Clinical Trials

RUATORIA-based Hikurangi Group has signed an agreement to work with Rhizo Sciences LLC, a cannabis industry development company based in Seattle, Washington. Hikurangi Group and Rhizo Sciences intend to establish the first pharmaceutical-grade GMP medical cannabis production and processing facility in New Zealand. This will allow Hikurangi Group to provide high-quality medical cannabis products to […]

by

The Food and Drug Administration (FDA), the Drug Enforcement Administration (DEA), and anti-cannabis activists like to claim that marijuana has no proven value as a medicine. Both the FDA and the DEA have resisted approval or funding for trials using actual marijuana. If marijuana has no medicinal value, why are there three FDA-approved pharmaceutical drugs […]

by

On 15 December 2017, the Danish Parliament adopted by unanimous vote a new Act on a pilot scheme on cannabis for medicinal use (the “Cannabis Act”). The scheme will be introduced on 1 January 2018. In anticipation of the final adoption of the Act, the Danish Medicines Agency (DMA) began in October 2017 to accept […]

by

Conditionally effective-patients with autism or sleep apnea can enroll July 1 and pick up medication Aug. 1. There are a statute-set limited number of outlets in this state. There are four in the Twin Cities and four in outstate Minnesota, which include St. Cloud, Rochester, Moorhead and Hibbing,” said Dr. Tom Arneson, research manager at […]

by

Vitality Biopharma has developed a cannabis-based potential treatment for inflammatory bowel diseases. Its annoucement about VITA-100 comes as U.S. regulators have been approving cannabis-based products for various disorders. VITA-100 delivers two of the active ingredients in cannabis plants to the intestinal tract to alleviate inflammation there. Those components are cannabidiol and tetrahydrocannabinol, or THC. Vitality calls the new class […]

by

CannaRoyalty to contribute Bodhi Research position into the JV in exchange for equity OTTAWA, Jan. 11, 2018 /CNW/ – CannaRoyalty Corp. (CSE: CRZ) (OTCQX: CNNRF) (“CannaRoyalty”) and Aequus Pharmaceuticals Inc. (TSX-V: AQS) (OTCQB: AQSZF) (“Aequus”) (together the “Partners”), today announced a collaboration (the “JV”) to advance a suite of cannabis-based therapies targeting neurological disorders into […]

by

By Glenn Ellis Depending on whom you talk to, medical marijuana (also known as cannabis) is either a panacea for everything from cancer, to chronic pain, to epilepsy or it’s a dangerous and illegal drug with no place in medicine. In 1996, California voters passed Proposition 215, making the Golden State the first in the […]

by

VANCOUVER, British Columbia, Jan. 10, 2018 (GLOBE NEWSWIRE) — Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP), (“Veritas” or the “Company”) is pleased to announce that its research arm, Cannevert Therapeutics Ltd. (“CTL”) has signed a clinical research agreement with the FDI Clinical Research (FDI-CR) in San Juan, Puerto Rico, to conduct the first human study of […]

by

Newswise — NEW YORK (January 10, 2018) – The Department of Defense (DOD) has awarded $1.3 million to fund a clinical trial at Montefiore Health System that will examine the effect of a cannabis compound called Cannabidivarin (CBDV) on irritability and repetitive behaviors in children with autism spectrum disorder (ASD). These characteristics are common in […]

by

SEATTLE, WA, Jan. 09, 2018 (GLOBE NEWSWIRE) — CFN Media Group (“CannabisFN”), the leading creative agency and media network dedicated to legal cannabis, announces publication of an exclusive CEO interview and article discussing Ehave Inc.(OTCQB: EHVVF) and its proprietary patient management platform, currently in use in both the medical marijuana and mental health industries. In the interview, CEO […]

by